Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million ...

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius ...

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) was upgraded by equities researchers at D. Boral Capital from a “hold” ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...

Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, ...

PitchBook’s VC-Backed IPO Index is up 68% through Dec. 27 and at its highest level in three years. We sell different types of products and services to both investment professionals and ...